99mTc-TRODAT-1, which binds to the dopamine transporter (DAT) located on the presynaptic nerve endings in striatum, has been reported by Dr. Hank F. Kung1 as a SPECT imaging agent for the diagnosing and monitoring of the progression of Parkinson’s Disease (PD). It was first developed in a commercially available form by the Institute of Nuclear Energy Research (INER) of Taiwan. The product was granted marketing approval by TFDA (Taiwan Food and Drug Administration) in 2005. In 2015, Global Medical Solution (GMS) Taiwan has acquired the ownership of this clinically proven product from INER. Ever since its launch a decade ago, 99mTc-TRODAT-1 has been commonly used in many countries (Taiwan, India, Brazil, etc.…) as an adjunct to other diagnostic modalities of PD. Today, more than 10,000 scans are performed annually worldwide with this product.
|Kit for the Preparation of Technetium Tc 99m Trodat-1 Injection
|Imaging of dopamine transporters located in the dopaminergic presynaptic neuron terminals in the striatum.
|Kits Per Box